Topics
High-grade gliomas | Treatment | Clinical trials | Re-irradiation
Home > Publications > Topics > High-grade gliomas > Treatment > Clinical trials > Re-irradiation
Sahebjam S, Raval RR, Forsyth PA, Enderling H, Tran ND, Arrington
JA, Macaulay R, Perlow HK, Palmer JD, Ghose J, Rajappa P, Giglio
P, Li Z, Etame AB, Mokhtari S, Cruz-Chamorro RJ, Bhandari M, Thapa
R, Robinson TJ, Chen DT, Yu HM.
Phase
1 trial of hypofractionated stereotactic re-irradiation in
combination with nivolumab, ipilimumab, and bevacizumab for
recurrent high-grade gliomas.
Neurooncol
Adv. 2025 Feb 8;7(1):vdaf033. doi:
10.1093/noajnl/vdaf033. PMID:
40134851. Interventional study. ˍ
de Jong AM, van der Boog ATJ, Post CCB, Cialdella F, Eekers DBP,
Hendrikse J, Kramer MCA, Lagerwaard FJ, van der Meulen M,
Philippens MEP, Robe PA, Rozema T, de Vos FYFL, Vos-Westerman J,
van der Weide HL, Wester G, Zindler J, Snijders TJ, Verhoeff JJC.
Study protocol for a multicenter phase
II prospective externally controlled non-inferiority trial of
hypofractionated re-irradiation in patients with recurrent
high-grade glioma (RISinG).
PLoS
One. 2026 Feb 9;21(2):e0342337. doi:
10.1371/journal.pone.0342337. PMID:
41662245. Interventional study protocol.
ˍ